RxDoctor Payments Data

Kevin Wienkers, MD

Ophthalmology · Green Bay, WINPI 1144241852

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,105 of the $2,922 with a category attached, or 72.0%. Johnson & Johnson Surgical Vision, Inc. accounts for 83.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $2,739 and has fallen 97.9% since, to $59 in 2023.

$2,922in general payments, 2019–2025

Across 33 payments — averaging $88.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$142
  • Alcon$113
  • Novartis$92
  • Bausch & Lomb Americas Inc.$77
  • The Cameron-ehlen Group, Inc.$44
  • plus $30 from 2 others

What the payments were for

  • Travel & lodging$2,10572%
  • Food & beverage$81728%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,922 in reported general payments places this provider in the 85th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$289,868
Medicare patients
541
Services billed
1,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate761$20,285
ProlensaBromfenac Sodium38$13,341
MoxifloxacinMoxifloxacin Hcl274$7,378
Bromfenac Sodium25$5,329
Latanoprost70$815
Diclofenac Sodium72$644
Timolol Maleate37$558
ErythromycinErythromycin Base41$348
Brimonidine Tartrate12$145
Tobramycin15$117
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$142$13,34138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →